Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity (Q42790618)

From Wikidata

Jump to navigation Jump to search

scientific article published on November 2010

Language	Label	Description	Also known as
English	Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity	scientific article published on November 2010

Statements

scholarly article

1 reference

7 November 2017

Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity (English)

1 reference

7 November 2017

methicillin-resistant Staphylococcus aureus

0 references

ceftaroline fosamil

1 reference

ChEBI release 2020-05-28

Staphylococcus aureus

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

George L Drusano

1

1 reference

7 November 2017

language of work or name

0 references

publication date

1 November 2010

1 reference

7 November 2017

Journal of Antimicrobial Chemotherapy

1 reference

7 November 2017

65 Suppl 4

1 reference

7 November 2017

iv33-9

1 reference

7 November 2017

Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ253

21 January 2018

Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ253

21 January 2018

Thrombocytopenia associated with linezolid therapy

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ253

21 January 2018

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ253

21 January 2018

Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ253

21 January 2018

TAK-599, a novel N-Phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ253

21 January 2018

In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ253

21 January 2018

Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ253

21 January 2018

Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ253

21 January 2018

Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ253

21 January 2018

Ceftaroline: a cephalosporin with expanded Gram-positive activity

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ253

21 January 2018

Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ253

21 January 2018

Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ253

21 January 2018

Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ253

21 January 2018

CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ253

21 January 2018

CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ253

21 January 2018

Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ253

21 January 2018

Identifiers

10.1093/JAC/DKQ253

1 reference

7 November 2017

1 reference

7 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42790618&oldid=2143964595"